Analysis of pharmacotherapy and compensation of arterial hypertension in patients with obstructive sleep apnea

• Published in: Sleep medicine Vol. 14; p. e274
• Main Authors: Sova, M, Sovova, E, Hobzova, M, Kamasova, M, Kolek, V
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.2013
• Subjects: Neurology; Sleep Medicine
• ISSN: 1389-9457; 1878-5506
• DOI: 10.1016/j.sleep.2013.11.671

Introduction Obstructive sleep apnea (OSA) is a common disorder with important clinical consequences. It is one of the most important causes of a secondary hypertension. Current European Society of Hypertension (ESH) guidelines offer relatively accurate manual how to treat arterial hypertension, but it is usually not known whether physicians are following these guidelines. The aim of this study was to analyze pharmacotherapy and compensation of arterial hypertension in patients with OSA. Materials and methods 98 hypertensive patients (86 men), average age 53.9 ± 0.9 years were evaluated using polysomnography with diagnosis of OSA, average apnea-hypopnea index (AHI) 54.6 ± 2.3. Patients underwent 24 h ambulatory blood pressure monitoring and current pharmacotherapy data was taken. Appropriate combinations of antihypertensive drugs were derived from ESH guidelines. Results 36 (36.7%) patients were taking appropriate combination of antihypertensive drugs. Compensated blood pressure evaluated by ABPM was present in 15 (15.3%) patients. From this group 7 (46.7%) patients were taking drugs according to guidelines. The most common therapy in optimal compensation group was ACEi/ARB (3 patients-20%) and ACEi/ARB + beta blocker (3 patients-20%). 9 (60%) patients were taking ACEi, average dose 6.4 mg of perindopril equivalent, 7 (46.7%) patients were taking beta blocker, average dose 62.5 mg of metoprolol equivalent. Conclusion In patients referred to sleep laboratory because of OSA symptoms is arterial hypertension treated according to current guidelines in only 36.7%. Arterial hypertension is not well compensated in 84.7% of patients. From these results is evident that optimalization of antihypertensive treatment can be in patients with OSA much better. Acknowledgement This study has been supported by grant: LF_2013_17.